One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
  • Pharmaceutical Composition
    Publication number: 20140037721
    Abstract: Provided herein are pharmaceutical compositions comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions are also demonstrated.
    Type: Application
    Filed: October 10, 2013
    Publication date: February 6, 2014
    Applicant: Alpharma pharmaceuticals LLC
    Inventors: Alfred Liang, Frank Matthews, Garth Boehm, Lijuan Tang, Frank Johnson, Joseph Stauffer
  • Toll-like receptor modulators and uses thereof
    Patent number: 8642614
    Abstract: The present invention provides a compound of the formula: where n, m, X1, X2, X3, X4, R1, R2 and R3 are those defined herein. Some aspects of the invention also provides methods for using these compounds and compositions comprising the same.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: February 4, 2014
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Hang Yin, Linda R. Watkins
  • Methods of using 8-carboxamido-2,6-methano-3-benzazocines
    Patent number: 8642615
    Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure I in which A is —CH2—OH, —CH2NH2, —NHSO2CH3, and Y is O, S or NOH are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications. 8-Carboxamides, thiocarboxamides, hydroxyamidines and formamides are preferred.
    Type: Grant
    Filed: July 24, 2012
    Date of Patent: February 4, 2014
    Assignee: Rensselaer Polytechnic Institute
    Inventor: Mark P. Wentland
  • TAMPER RESISTANT DOSAGE FORMS
    Publication number: 20140030327
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 30, 2014
    Applicant: PURDUE PHARMA L.P.
    Inventor: Purdue Pharma L.P.
  • Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose
    Publication number: 20140030343
    Abstract: The invention relates to compositions and methods for attenuating opioid induced respiratory depression. Such compositions comprise opioids and sequestered opioid antagonists in a multi-particulate dosage formulation.
    Type: Application
    Filed: October 25, 2011
    Publication date: January 30, 2014
    Applicant: Alpharma Pharmaceuticals LLC
    Inventors: Michael J. Lamson, Veeraindar Goli
  • Chemosensory Receptor Ligand-Based Therapies
    Publication number: 20140030332
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Application
    Filed: January 6, 2012
    Publication date: January 30, 2014
    Applicant: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley, Mark S. Fineman
  • DOSAGE FORM CONTAINING OXYCODONE AND NALOXONE
    Publication number: 20140031382
    Abstract: The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, Cmax, AUCt value, mean bowel function score and/or duration of analgesic efficacy.
    Type: Application
    Filed: October 2, 2013
    Publication date: January 30, 2014
    Applicant: Euro-Celtique S.A.
    Inventors: Petra LEYENDECKER, Michael Hopp, Kevin Smith
  • 3-CARBOXYPROPYL-AMINOTETRALIN DERIVATIVES AND RELATED COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20140031380
    Abstract: The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: June 19, 2013
    Publication date: January 30, 2014
    Applicant: THERAVANCE, INC.
    Inventors: Sean G. Trapp, Michael R. Leadbetter, Daniel D. Long, John R. Jacobsen, Priscilla Van Dyke
  • TAMPER RESISTANT DOSAGE FORMS
    Publication number: 20140031381
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: September 27, 2013
    Publication date: January 30, 2014
    Applicant: PURDUE PHARMA L.P.
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Compositions for deterring abuse of opioid containing dosage forms
    Patent number: 8637540
    Abstract: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.
    Type: Grant
    Filed: June 25, 2013
    Date of Patent: January 28, 2014
    Assignee: Acura Pharmaceuticals
    Inventors: Vijai Kumar, David Dixon, Divya Tewari, Dilip B. Wadgaonkar
  • Methods for treatment of pruritis
    Patent number: 8637538
    Abstract: The present invention relates to methods for treating uremic pruritus with anti-pruritic compositions.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: January 28, 2014
    Assignee: Trevi Therapeutics, Inc.
    Inventor: Thomas Sciascia
  • Remedies for neuropathic pain and model animals of neuropathic pain
    Patent number: 8637539
    Abstract: The present invention relates to a therapeutic agent for neuropathic pain containing, as an active ingredient, a compound represented by general formula (I) or a pharmacologically acceptable acid addition salt thereof: (wherein R1, R2, R3, R4, R5, R6, R7, R8, A, and B have the same definitions as those described in the specification), and an animal model produced by administering (+)-4a-(3-hydroxyphenyl)-2-methyl-1,2,3,4,4a,5,12,12a-octohydro-trans-quinolino[2,3-g]isoquinoline. The present invention makes it possible to perform drug treatment for neuropathic pain. The therapeutic effect of a compound against neuropathic pain can also be evaluated.
    Type: Grant
    Filed: August 18, 2005
    Date of Patent: January 28, 2014
    Assignee: Toray Industries, Inc.
    Inventors: Hiroshi Nagase, Takashi Endo, Kuniaki Kawamura, Toshiaki Tanaka, Tomohiko Suzuki, Tsutomu Suzuki, Yasushi Kuraishi, Kimiyasu Shiraki
  • NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OPIOID DEPENDENCE
    Publication number: 20140023704
    Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
    Type: Application
    Filed: March 13, 2013
    Publication date: January 23, 2014
    Applicant: Orexo AB
    Inventor: Andreas Fischer
  • TAMPER RESISTANT DOSAGE FORMS
    Publication number: 20140024669
    Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 23, 2014
    Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
  • Extended Release, Abuse Deterrent Pharmaceutical Compositions
    Publication number: 20140017310
    Abstract: The present disclosure provides pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, optionally at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties. Also provided are methods for preparing the pharmaceutical compositions in which the components of the composition are humidified such that the deliquescent plasticizer deliquesces, thereby plasticizing the hydrophilic polymers.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 16, 2014
    Inventors: Brad L. Gower, Carlos H. Castaneda, Jae Han Park, Clifford J. Herman
  • Encased Tamper Resistant Controlled Release Dosage Forms
    Publication number: 20140010875
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Application
    Filed: September 11, 2013
    Publication date: January 9, 2014
    Applicant: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • USE OF OPIOID ANTAGONISTS
    Publication number: 20140011831
    Abstract: Embodiments of the invention provide methods of attenuating, e.g., inhibiting or reducing, cellular proliferation and migration, particularly endothelial cell proliferation and migration, including that associated with angiogenesis, as well as attenuating cancerous tumor growth and metastasis, using opioid antagonists, including, but not limited to, those that are peripherally restricted antagonists.
    Type: Application
    Filed: August 21, 2013
    Publication date: January 9, 2014
    Applicant: The University of Chicago
    Inventors: Jonathan Moss, Mark Lingen, Patrick A. Singleton, Joe G.N. Garcia
  • Encased Tamper Resistant Controlled Release Dosage Forms
    Publication number: 20140011832
    Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
    Type: Application
    Filed: September 11, 2013
    Publication date: January 9, 2014
    Applicant: Purdue Pharma L.P.
    Inventor: Haiyong Hugh Huang
  • ABUSE DETERRENT PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED RELEASE
    Publication number: 20140010873
    Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 9, 2014
    Inventors: Peter Holm Tygesen, Karsten Lindhardt, Martin Rex Olsen, Gina Engslev Fischer, Jan Martin Overgard, Georg Boye, Nikolaj Skak, Torben Elhauge
  • 3-oxy-hydromorphone derivatives
    Patent number: 8623888
    Abstract: The present invention provides 3-oxy-hydromorphone derivatives, and in particular, 3-ester, 3-carbonate, and 3-sulfonate derivatives of hydromorphone.
    Type: Grant
    Filed: July 9, 2010
    Date of Patent: January 7, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Gary L. Cantrell, Robert E. Halvachs, Frank W. Moser, David W. Berberich, Peter X. Wang
  • SUBLINGUAL AND BUCCAL FILM COMPOSITIONS
    Publication number: 20140005218
    Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.
    Type: Application
    Filed: August 12, 2013
    Publication date: January 2, 2014
    Applicant: RB Pharmaceuticals Limited
    Inventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, Beuford A. Bogue, Pradeep Sanghvi, Madhusudan Hariharan
  • Nalmefene for reduction of alcohol consumption in specific target populations
    Publication number: 20140005217
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains a high DRL after an observation period following initial assessment.
    Type: Application
    Filed: June 26, 2013
    Publication date: January 2, 2014
    Inventors: Lars Torup, Afsaneh Abbariki, Anna Bladstrom, Christine Persson, Didier Meulien, Per Sorensen, Thomas Jon Jensen, Jette Buch Ostergaard
  • ORAL PHARMACEUTICAL DISPERSION COMPOSITIONS
    Publication number: 20140005179
    Abstract: The invention provides an oral pharmaceutical composition, optionally in dose unit form, comprising a lipophilic drug substance in dispersion in a physiologically tolerable aqueous carrier, preferably an aqueous gel, wherein said drug substance contains a functional electrostatic group having a pKa value of from 2 to 10, characterised in that said aqueous carrier has a pH at least 0.3 below or above said pKa value, said pH being below said pKa where said group is acidic and above said pKa where said group is basic.
    Type: Application
    Filed: April 11, 2011
    Publication date: January 2, 2014
    Applicant: AYANDA GROUP AS
    Inventors: Kurt Ingar Draget, Ingvild Haug, Magnus N. Hattrem, Tore Seternes, Steinar Johan Engelsen
  • Nalmefene for reduction of alcohol consumption in specific target populations
    Publication number: 20140005216
    Abstract: The present invention relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who has a high drinking risk level. The present invention also relates to nalmefene for use in the reduction of alcohol consumption in a patient with alcohol dependence who maintains at least medium DRL after an observation period following initial assessment.
    Type: Application
    Filed: June 26, 2013
    Publication date: January 2, 2014
    Inventors: Lars Torup, Afsaneh Abbariki, Anna Bladström, Christine Persson, Didier Meulien, Per Sørensen, Thomas Jon Jensen, Jette Buch Østergaard
  • Selective Opioid Compounds
    Publication number: 20140005215
    Abstract: The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which relates to mophinan compounds useful as ?, ? and/or ? receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.
    Type: Application
    Filed: December 4, 2012
    Publication date: January 2, 2014
    Applicant: Alkermes, Inc.
    Inventor: Alkermes, Inc.
  • INTRATHECAL HYDROMORPHONE SOLUTIONS HAVING IMPROVED STABILITY
    Publication number: 20140005219
    Abstract: The present disclosure relates generally to a pharmaceutical solution comprising hydromorphone or a pharmaceutically acceptable salt thereof that is substantially free of buffer and optionally one or more other additives. The pharmaceutically acceptable salt may be hydromorphone hydrochloride. Also disclosed are methods for the manufacture and use of the solution.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 2, 2014
    Inventors: John J. Foster, Thomas R. Prentice
  • PRODUCTION OF MULTIVESICULAR LIPOSOMES
    Publication number: 20140004173
    Abstract: Multivesicular liposomes are prepared at commercial scales by combining a first w/o emulsion with a second aqueous solution to form a w/o/w emulsion using a static mixer. Solvent is removed from the resulting emulsion to form multivesicular liposome-containing compositions. Further optional process steps include primary filtration and secondary cross-flow filtration. The products produced according to the processes of the invention can be produced through a series of aseptic steps.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 2, 2014
    Applicant: Pacira Pharmaceuticals, Inc.
    Inventor: Pacira Pharmaceuticals, Inc.
  • CRYSTAL FORMS OF (R)-N-METHYLNALTREXONE BROMIDE AND USES THEREOF
    Publication number: 20140004188
    Abstract: The present invention provides a new forms of (R)—N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
    Type: Application
    Filed: November 21, 2012
    Publication date: January 2, 2014
    Inventors: Progenics Pharmaceuticals, Inc., Wyeth, LLC
  • ANTI-NAUSEA DRUG COMBINATIONS
    Publication number: 20130345250
    Abstract: Methods and compositions are disclosed for reducing Post Operative Nausea and/or Vomiting (PONV) in a human patient in need of general anesthesia. Such methods may include scheduling surgery for the human patient and administering to the patient one or more series of prescribed medicines days during a regimen preceding general anesthesia to condition receptors involved in the nausea and/or vomiting reflex.
    Type: Application
    Filed: June 14, 2013
    Publication date: December 26, 2013
    Inventor: C. Andrew Fleming
  • FORMULATIONS OF NONOPIOID AND CONFINED OPIOID ANALGESICS
    Publication number: 20130344143
    Abstract: The preferred exemplary embodiments in the present application provide formulations and methods for the delivery of drugs, particularly drugs of abuse, having an abuse-relevant drug substantially confined in the core and a non-abuse relevant drug in a non-core region. These formulations have reduced potential for abuse. In the formulation, preferably the abuse relevant drug is an opioid and the non-abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non-abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.
    Type: Application
    Filed: December 28, 2012
    Publication date: December 26, 2013
    Inventors: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
  • LARGE SUBSTITUENT, NON-PHENOLIC OPIOIDS AND METHODS OF USE THEREOF
    Publication number: 20130345251
    Abstract: 8-Substituted-2,6-methano-3-benzazocines of general structure are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
    Type: Application
    Filed: August 23, 2013
    Publication date: December 26, 2013
    Applicant: Rensselaer Polytechnic Institute
    Inventor: Mark P. WENTLAND
  • Sinomenine derivatives and processes for their synthesis
    Patent number: 8614224
    Abstract: The invention generally provides processes and intermediate compounds useful for the production of sinomenine derivatives. In particular, the process may encompass synthetic routes for the production of (+)-sinomenine derivatives and their intermediates.
    Type: Grant
    Filed: January 18, 2012
    Date of Patent: December 24, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Peter X. Wang, Tao Jiang, Gary L. Cantrell, David W. Berberich, Bobby N. Trawick, Subo Liao, John Brandt
  • Pharmaceutical Compositions
    Publication number: 20130337020
    Abstract: Provided herein is a method of treating a condition in a host that is responsive to an agonist, the method comprising administering to the host a multi-layer pharmaceutical composition comprising the agonist and an antagonist thereof, wherein the agonist and antagonist are not in direct contact with one another in the intact form of the composition.
    Type: Application
    Filed: August 21, 2013
    Publication date: December 19, 2013
    Applicant: Alpharma Pharmaceuticals LLC
    Inventors: Frank Matthews, Alfred C Liang, Frank Johnson
  • TREATMENT OF EFFECT OF CHEMICALS WITH THEIR ULTRADILUTE STEREOISOMERS
    Publication number: 20130338181
    Abstract: A method of treating an effect of a chemical agent, which agent is characterized by one or more chiral centres, by administering a dilution or an ultra-high dilution or potentised preparation of a stereoisomer of said chemical agent.
    Type: Application
    Filed: August 18, 2013
    Publication date: December 19, 2013
    Inventor: Reinhard Michael Kuzeff
  • Oral Pharmaceutical Dosage Forms
    Publication number: 20130337060
    Abstract: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.
    Type: Application
    Filed: March 5, 2013
    Publication date: December 19, 2013
    Applicant: Durect Corporation
    Inventor: Durect Corporation
  • Oral Pharmaceutical Dosage Forms
    Publication number: 20130337059
    Abstract: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.
    Type: Application
    Filed: March 5, 2013
    Publication date: December 19, 2013
    Applicant: Durect Corporation
    Inventor: Durect Corporation
  • Analgesic agents
    Patent number: 8609682
    Abstract: The invention provides a compound of formula (I) or a salt thereof, as well as compositions comprising such compounds. The compounds and compositions are useful as analgesics.
    Type: Grant
    Filed: July 10, 2009
    Date of Patent: December 17, 2013
    Assignee: Regents of The University of Minnesota
    Inventors: Philip S. Portoghese, Ajay S. Yekkirala
  • Pharmaceutical formulation containing gelling agent
    Patent number: 8609683
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: December 17, 2013
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Dosage Form
    Publication number: 20130330409
    Abstract: The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising; non-stretched melt extruded particulates comprising a drug selected from an opioid agonist, a tranquilizer, a CNS depressant, a CNS stimulant or a sedative hypnotic; and a matrix; wherein said melt extruded particulates are present as a discontinuous phase in said matrix.
    Type: Application
    Filed: December 9, 2011
    Publication date: December 12, 2013
    Applicant: Euro-Celtique S.A.
    Inventor: Hassan Mohammad
  • ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE
    Publication number: 20130330407
    Abstract: The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: Wyeth, LLC
    Inventors: Syed M. SHAH, Christopher Richard Diorio, Eric C. Ehrnsperger, Xu Meng, Kadum A. Al Shareffi, Jonathan Marc Cohen
  • SYNTHESIS OF R-N-METHYLNALTREXONE
    Publication number: 20130323286
    Abstract: This invention relates to stereoselective synthesis of R-MNTX and intermediates thereof, pharmaceutical preparations comprising R-MNTX or intermediates thereof and methods for their use.
    Type: Application
    Filed: November 7, 2012
    Publication date: December 5, 2013
    Applicant: PROGENICS PHARMACEUTICALS, INC.
    Inventor: Progenics Pharmaceuticals, Inc.
  • Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
    Patent number: 8597681
    Abstract: Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: December 3, 2013
    Assignee: Mallinckrodt LLC
    Inventors: Jae Han Park, Tiffani Eisenhauer, Anish Dhanarajan, Vishal K. Gupta, Stephen Overholt
  • METHODS FOR TREATMENT AND PREVENTION OF OPIOID INDUCED CONSTIPATION USING ORAL COMPOSITIONS OF METHYLNALTREXONE
    Publication number: 20130317050
    Abstract: Presented herein are methods for treatment or prevention of opioid induced constipation by administration of oral compositions of methylnaltrexone. The methods are based, at least in part, on the identification of subjects that are particularly susceptible to such treatment and optimal dosages of such oral compositions to treat or prevent opioid induced constipation and, further, to minimize the occurrence of adverse events associated with such treatment.
    Type: Application
    Filed: December 19, 2012
    Publication date: November 28, 2013
    Inventor: Enoch BORTEY
  • Methods Useful for the Treatment of Pain, Arthritic Conditions or Inflammation Associated with a Chronic Condition
    Publication number: 20130317049
    Abstract: Methods, including those for administering novel pharmaceutical compositions, dosage forms containing an opioid active pharmaceutical ingredient, are useful for treating pain, arthritic conditions and/or inflammation associated with a chronic condition, including pain from arthritis and inflammation.
    Type: Application
    Filed: October 22, 2012
    Publication date: November 28, 2013
    Applicant: Durect Corporation
    Inventors: Su Il Yum, Wendy Chao, Roger Fu, Michael Zamloot
  • ABUSE-DETERRENT DRUG FORMULATIONS
    Publication number: 20130310413
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.
    Type: Application
    Filed: April 25, 2013
    Publication date: November 21, 2013
    Applicant: Collegium Pharmaceutical, Inc.
    Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Kilbanov
  • Opiod Agonist Formulations with Releasable And Sequestered Antagonist
    Publication number: 20130309303
    Abstract: Disclosed are oral dosage forms, comprising (i) a therapeutically effective amount of an opioid agonist; (ii) an opioid antagonist in releasable form; and (iii) a sequestered opioid antagonist which is not released when the dosage form is administered intact, and methods thereof.
    Type: Application
    Filed: July 29, 2013
    Publication date: November 21, 2013
    Applicant: Purdue Pharma L.P.
    Inventors: Christopher Breder, Curtis Wright, Benjamin Oshlack
  • Combinations of an Opioid/TLR4 Antagonist and a Direct-Acting Alpha-2 Adrenergic Agonist for Use in the Treatment of Pain
    Publication number: 20130310412
    Abstract: Disclosed are compositions for treatment of pain comprising a first compound and a second compound, where the first compound is an opioid antagonist that treats pain by blocking Toll-like receptor 4 (TLR4) and the second compound is a direct-acting alpha-2 adrenergic agonist that enhances the pain treatment effect and abates adverse effects of the first compound, synergistic pharmaceutical compositions thereof, and their use in the treatment, prevention, and reversal of pain, particularly neuropathic pain.
    Type: Application
    Filed: March 13, 2013
    Publication date: November 21, 2013
    Inventor: Annette Channa Toledano
  • THERAPEUTIC OR PROPHYLACTIC AGENT FOR CACHEXIA
    Publication number: 20130310414
    Abstract: A therapeutic or prophylactic agent for cachexia includes as an effective ingredient a compound having a specified morphinan skeleton represented by a compound of the following structure: or a pharmacologically acceptable acid addition salt thereof.
    Type: Application
    Filed: January 30, 2012
    Publication date: November 21, 2013
    Applicant: Toray Industries, Inc.
    Inventors: Tomohiko Suzuki, Yoshitaka Yoshizawa, Mikito Hirakata
  • MORPHINE AND MORPHINE PRECURSORS
    Publication number: 20130309326
    Abstract: Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided.
    Type: Application
    Filed: June 21, 2013
    Publication date: November 21, 2013
    Applicant: The Research Foundation of State University of New York
    Inventors: George B. Stefano, Patrick Cadet, Kirk J. Mantione, Wei Zhu
  • Tamper-resistant oral opioid agonist formulations
    Patent number: 8586088
    Abstract: Disclosed is an oral dosage form comprising: (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is not released when the dosage form is administered orally intact.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: November 19, 2013
    Assignee: Purdue Pharma L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J. David Haddox